Executive Summary

Oct 2019
PROSPECTS
Analgesics continue to see demand grow

Analgesics posted positive growth in 2019. More analgesics are targeting specific pain.

Delay in codeine restriction

There has been a delay in codeine becoming a prescription-only drug in New Zealand, from January 2020 to a date that will be released later by Medsafe, after working with patient groups, health practitioners and healthcare professionals. The delay has been due to concerns that manufacturers would not have enough time to prepare for the changes, and there was a need to publicise the news widely before making it official.

Topical analgesics growing in demand

Due to the increasing pursuit of healthy lifestyles and a rise in the number of people going to the gym and playing sports, topical analgesics are growing in demand. This is also one of the fastest growing categories because of the ageing population in New Zealand, and more people using topical analgesics for joint and muscle pain.

COMPETITIVE LANDSCAPE
The leading company, GlaxoSmithKline, acquires Pfizer

Both GlaxoSmithKline and Pfizer have a range of popular pain relief treatments that can be purchased over the counter without a prescription. The companies are, however, not close competitors in New Zealand in analgesics, and there are other competing companies that supply products in the category, thus the Commerce Commission has granted clearance for the acquisition of Pfizer by GlaxoSmithKline.

AFT Pharmaceuticals’ product Maxigesic gains traction

Although AFT Pharmaceuticals’ sales in New Zealand have declined marginally, the country still accounts for the majority of the company’s sales, along with Australia. The company’s product Maxigesic has been doing well, and distribution has been expanded to other countries, including the UK, Brunei, El Salvador, Israel, Iraq/Kurdistan, Ireland, Italy, Malaysia, Malta, Nicaragua, Serbia, Singapore and the United Arab Emirates.

Want to find out more about this report?
Request more information
Why buy this report?

Gain competitive intelligence about market leaders. Track key industry trends, opportunities and threats. Inform your marketing, brand, strategy and market development, sales and supply functions.

Your Recently Viewed Reports

Analgesics in New Zealand

Samples (FAQs about samples):

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Analgesics industry in New Zealand with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Analgesics industry in New Zealand, our research will save you time and money while empowering you to make informed, profitable decisions.

The Analgesics in New Zealand market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Analgesics in New Zealand?
  • What are the major brands in New Zealand?
  • Are combination products with acetaminophen still popular?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Analgesics in New Zealand - Category analysis

HEADLINES

PROSPECTS

Analgesics continue to see demand grow
Delay in codeine restriction
Topical analgesics growing in demand

COMPETITIVE LANDSCAPE

The leading company, GlaxoSmithKline, acquires Pfizer
AFT Pharmaceuticals’ product Maxigesic gains traction

CATEGORY DATA

Table 1 Sales of Analgesics by Category: Value 2014-2019
Table 2 Sales of Analgesics by Category: % Value Growth 2014-2019
Table 3 NBO Company Shares of Analgesics: % Value 2015-2019
Table 4 LBN Brand Shares of Analgesics: % Value 2016-2019
Table 5 Forecast Sales of Analgesics by Category: Value 2019-2024
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2019-2024

Consumer Health in New Zealand - Industry Overview

EXECUTIVE SUMMARY

Consumer health industry fuelled by growing demand for complementary medicines
Specific health areas gaining traction with more natural offerings
Vitamin and dietary supplement players revamp packaging
Discount pharmacy Chemist Warehouse is changing the retailing landscape
Positive outlook for consumer health

MARKET INDICATORS

Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019
Table 8 Consumer Expenditure on Health Goods and Medical Services: Value 2014-2019

MARKET DATA

Table 9 Sales of Consumer Health by Category: Value 2014-2019
Table 10 Sales of Consumer Health by Category: % Value Growth 2014-2019
Table 11 NBO Company Shares of Consumer Health: % Value 2015-2019
Table 12 LBN Brand Shares of Consumer Health: % Value 2016-2019
Table 13 Penetration of Private Label in Consumer Health by Category: % Value 2014-2019
Table 14 Distribution of Consumer Health by Format: % Value 2014-2019
Table 15 Distribution of Consumer Health by Format and Category: % Value 2019
Table 16 Forecast Sales of Consumer Health by Category: Value 2019-2024
Table 17 Forecast Sales of Consumer Health by Category: % Value Growth 2019-2024

APPENDIX

OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
Summary 1 OTC: Switches 2018-2019

DEFINITIONS

SOURCES

Summary 2 Research Sources